DỊCH VỤ NÀY KHÔNG CÓ SẴN Ở KHU VỰC CỦA BẠN

6 4 G LTD

Vương quốc Anh

Năm

2015 (11 Năm)

Được thành lập

Trực tuyến lần cuối: Không có hoạt động gần đây

Truy cập trang web

Chưa có TrustScoreChưa đủ điểm để hiển thị xu hướng.

Hãy là người đầu tiên đánh giá và nhận xét công ty này.

ĐIỂM TỔNG THỂ

Giấy phép

--/40

Đánh giá

--/60

0 đánh giá

Được cung cấp bởi TrustFinance

Chưa có TrustScoreChưa đủ điểm để hiển thị xu hướng.

Hãy là người đầu tiên đánh giá và nhận xét công ty này.

Được quy định

Được đề xuất

IUX

(2,283 đánh giá)

Mauritius

2016

(10 năm)

Thông tin Bảo mật :

FSCA

FSC

ASIC

Thông tin Bảo mật

Cảnh báo

Công ty này hiện đang Chưa được chứng minh.

Hãy thận trọng với những rủi ro tiềm ẩn!

Giấy phép

Giấy phép hạng A

Được cấp bởi các cơ quan quản lý nổi tiếng toàn cầu, các giấy phép này đảm bảo sự bảo vệ cao nhất cho nhà giao dịch thông qua tuân thủ nghiêm ngặt, tách biệt quỹ, bảo hiểm và kiểm toán thường xuyên. Giải quyết tranh chấp và tuân thủ các tiêu chuẩn AML/CTF giúp tăng cường bảo mật hơn nữa.

Giấy phép hạng B

Được cấp bởi các cơ quan quản lý khu vực uy tín, các giấy phép này cung cấp các biện pháp an toàn mạnh mẽ như tách biệt quỹ, báo cáo tài chính và chương trình bồi thường. Mặc dù ít nghiêm ngặt hơn so với Cấp 1, nhưng chúng cung cấp sự bảo vệ khu vực đáng tin cậy.

Giấy phép hạng C

Được cấp bởi các cơ quan quản lý tại các thị trường mới nổi, các giấy phép này cung cấp các biện pháp bảo vệ cơ bản như yêu cầu vốn tối thiểu và chính sách AML. Giám sát ít nghiêm ngặt hơn, vì vậy các nhà giao dịch nên thận trọng và xác minh các biện pháp an toàn.

Giấy phép hạng D

Từ các khu vực pháp lý có sự giám sát tối thiểu, các giấy phép này thường thiếu các biện pháp bảo vệ quan trọng như tách biệt quỹ và bảo hiểm. Mặc dù hấp dẫn về tính linh hoạt trong hoạt động, nhưng chúng gây ra rủi ro cao hơn cho các nhà giao dịch.

Thông tin công ty

Làm quen 6 4 G LTD

Hiển thị thêm

Thông tin công ty

Làm quen 6 4 G LTD

6 4 G LTD, operating under the brand name 64FX, is an online trading provider incorporated in St. Vincent & the Grenadines. The company's mission is to offer a transparent and high-quality trading environment for both retail and institutional clients. It provides access to global financial markets, including Forex, indices, commodities, and shares, utilizing the popular MetaTrader 5 trading platform and offering various account types to suit different trading needs.

Hiển thị thêm

Ngành công nghiệp

Ngoại hối Nhà môi giới bán lẻCHÍNH
Tài chính Dịch vụ khác

Phần mềm

Không có dữ liệu có sẵn

Có vẻ như phần này trống. Hãy quay lại sớm để cập nhật!

Liên hệ

Mạng xã hội

Công ty chưa cập nhật thông tin.

Đánh giá

6 4 G LTD Đánh giá

Đánh giá

Tổng 0

Xếp

Bộ lọc

Thông tin công ty

Làm quen 6 4 G LTD

Hiển thị thêm

Thông tin công ty

Làm quen 6 4 G LTD

6 4 G LTD, operating under the brand name 64FX, is an online trading provider incorporated in St. Vincent & the Grenadines. The company's mission is to offer a transparent and high-quality trading environment for both retail and institutional clients. It provides access to global financial markets, including Forex, indices, commodities, and shares, utilizing the popular MetaTrader 5 trading platform and offering various account types to suit different trading needs.

Hiển thị thêm

Ngành công nghiệp

Ngoại hối Nhà môi giới bán lẻCHÍNH
Tài chính Dịch vụ khác

Phần mềm

Không có dữ liệu có sẵn

Có vẻ như phần này trống. Hãy quay lại sớm để cập nhật!

Liên hệ

Mạng xã hội

Công ty chưa cập nhật thông tin.

Tin tức

TrustFinance Cơ quan Tình báo

Ngày nghiên cứu: Thg 05 14, 2026

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

Được cung cấp bởi Phân tích AI của TrustFinance

Tin tức

TrustFinance Cơ quan Tình báo

Ngày nghiên cứu: Thg 05 14, 2026

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

Được cung cấp bởi Phân tích AI của TrustFinance

6 4 G LTD

IUX

Thông tin công ty

Thông tin công ty